Abstract Background Infestation of cats with the Australian paralysis tick, Ixodes holocyclus continues to be a threat because of the paralysis that can result from attachment of just a single tick. The outcome can be fatal, particularly if tick removal and treatment is not initiated soon after the onset of paralysis. However, there are no published studies to guide veterinarians and owners on preventive measures. A study was therefore initiated to determine the efficacy of a systemically-acting, spot-on formulation of fluralaner (Bravecto®) for cats against existing I. holocyclus infestations, and to investigate the duration of protection following a single administration. Methods Healthy domestic cats, short or long-hair, immunized agains...
Background: A negative-controlled, randomized, blinded laboratory study in 31 cats was carried out ...
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically appli...
Abstract Background The efficacy of the fixed combination of fluralaner plus moxidectin for the trea...
Abstract Background A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/m...
Abstract Background Ticks are increasingly reported on cats worldwide, with Ixodes ricinus being a r...
Abstract Background Fluralaner (Bravecto®, Merck Animal Health, Madison, NJ, USA) is a novel isoxazo...
Abstract Background Cats can be infested with several ectoparasite species, especially Ctenocephalid...
Abstract Background There is a continuing need for novel approaches to tick infestations treatment a...
Abstract Background Lotilaner, approved for dogs as a chewable tablet formulation, has separately be...
Abstract Background The objectives of the studies listed here were to ascertain the therapeutic and ...
AbstractFive controlled, blinded and randomized studies were conducted to examine the efficacy of a ...
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically appl...
Abstract Background A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/m...
Background: Fluralaner is a novel isoxazoline compound and the only systemically distributed ectopa...
Abstract Background The effica...
Background: A negative-controlled, randomized, blinded laboratory study in 31 cats was carried out ...
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically appli...
Abstract Background The efficacy of the fixed combination of fluralaner plus moxidectin for the trea...
Abstract Background A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/m...
Abstract Background Ticks are increasingly reported on cats worldwide, with Ixodes ricinus being a r...
Abstract Background Fluralaner (Bravecto®, Merck Animal Health, Madison, NJ, USA) is a novel isoxazo...
Abstract Background Cats can be infested with several ectoparasite species, especially Ctenocephalid...
Abstract Background There is a continuing need for novel approaches to tick infestations treatment a...
Abstract Background Lotilaner, approved for dogs as a chewable tablet formulation, has separately be...
Abstract Background The objectives of the studies listed here were to ascertain the therapeutic and ...
AbstractFive controlled, blinded and randomized studies were conducted to examine the efficacy of a ...
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically appl...
Abstract Background A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/m...
Background: Fluralaner is a novel isoxazoline compound and the only systemically distributed ectopa...
Abstract Background The effica...
Background: A negative-controlled, randomized, blinded laboratory study in 31 cats was carried out ...
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically appli...
Abstract Background The efficacy of the fixed combination of fluralaner plus moxidectin for the trea...